Antiphospholipid Syndrome

  1. Overview
  2. Epidemiology
  3. Pathophysiology
  4. Classification Criteria
  5. Clinical Presentation
  6. Diagnosis
  7. Treatment
  8. Catastrophic APS
  9. Prognosis and Long-Term Management
  10. Research Papers
  11. Connections

Overview

Antiphospholipid Syndrome (APS) is an autoimmune thrombophilic disorder in which the immune system produces antibodies that mistakenly target certain proteins bound to phospholipids — components of cell membranes. The result is a paradoxical state of hypercoagulability despite a test called the "lupus anticoagulant" that prolongs clotting times in the laboratory. APS is defined by the combination of one or more clinical events — venous or arterial thrombosis, or recurrent adverse pregnancy outcomes — together with persistently positive antiphospholipid antibodies (aPL) confirmed on two separate occasions at least 12 weeks apart.

The syndrome can be primary APS, occurring in otherwise healthy individuals with no underlying autoimmune disease, or secondary APS, most commonly arising in the context of systemic lupus erythematosus (SLE). Roughly 30–40% of SLE patients carry antiphospholipid antibodies, making SLE the most frequent associated condition.

One of the most counterintuitive aspects of APS is the "lupus anticoagulant" paradox. In a test tube, lupus anticoagulant antibodies prolong phospholipid-dependent clotting assays (such as the APTT), creating the appearance of an anticoagulant effect. In the body, however, these same antibodies promote clotting. The mechanism involves the binding of aPL to the protein beta-2-glycoprotein I (β2GPI), which normally acts as a natural anticoagulant. When aPL-β2GPI complexes form, they activate complement, upregulate tissue factor on endothelial cells, and impair protein C activation — all of which strongly tip the balance toward thrombosis rather than bleeding.

Because the clinical consequences — stroke, deep vein thrombosis, pulmonary embolism, and pregnancy loss — are common and the underlying antibody-mediated mechanism is treatable, accurate recognition of APS is critically important.

Back to Table of Contents

Epidemiology

APS affects an estimated 40–50 people per 100,000 in the general population, making it one of the more common acquired thrombophilias. The condition has a striking female predominance, with a female-to-male ratio of approximately 5:1, reflecting its overlap with other autoimmune conditions that disproportionately affect women.

Among reproductive-age women, APS is clinically significant as a cause of recurrent pregnancy loss: it accounts for 10–15% of all cases of recurrent miscarriage. In the younger stroke population (individuals under 50), APS is responsible for an estimated 15–20% of ischemic strokes, making it one of the most important treatable causes of stroke in young adults.

Antiphospholipid antibodies are found in 30–40% of patients with systemic lupus erythematosus (SLE), though not all of these individuals will develop clinical APS. In the general population, approximately 1–5% of people test positive for antiphospholipid antibodies, but the vast majority of these positive tests represent transient elevations associated with infections rather than true autoimmune APS. Only persistent positivity on repeat testing 12 weeks apart carries clinical significance.

APS can manifest at any age but most commonly presents during the reproductive years (20s–40s). It is rare in children, though pediatric cases of thrombotic APS do occur, often in the setting of a viral trigger or SLE. There is no well-established geographic or ethnic predisposition, though some studies suggest higher antiphospholipid antibody prevalence in certain autoimmune-prone populations.

Back to Table of Contents

Pathophysiology

The three antibody types that define APS laboratory criteria — lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-beta-2-glycoprotein I antibodies (anti-β2GPI) — all converge on a common final pathway of accelerated thrombosis, though through distinct mechanisms.

Beta-2-glycoprotein I (β2GPI) as the central autoantigen: Although APS antibodies were originally described as targeting phospholipids (hence "antiphospholipid"), the true autoantigen in most cases is β2GPI, a plasma protein that binds to anionic phospholipids on cell membrane surfaces. In healthy individuals, β2GPI acts as a natural anticoagulant by displacing clotting factor complexes from phospholipid surfaces and by activating protein C. When autoantibodies bind β2GPI — particularly at its domain I — they convert it from an anticoagulant into a pro-thrombotic signal.

Mechanisms of thrombosis:

Obstetric APS mechanism: In pregnancy, the dominant mechanism is dual: placental thrombosis from the mechanisms above, compounded by direct complement-mediated injury to trophoblast cells. Anti-β2GPI antibodies can bind trophoblasts, triggering complement deposition and impairing trophoblast invasion and differentiation, leading to spiral artery remodeling failure, placental insufficiency, and pregnancy loss — even before the gestational age at which thrombosis of large vessels is the primary risk.

Back to Table of Contents

Sapporo / Revised Classification Criteria (2006)

The internationally accepted standard for classifying APS is the Revised Sapporo Criteria (also called the Sydney Criteria), published in 2006. For a diagnosis of APS, a patient must meet at least one clinical criterion AND at least one laboratory criterion.

Clinical criteria:

Laboratory criteria (must be positive on 2+ occasions, at least 12 weeks apart):

Triple positivity — simultaneous positivity for all three antibody types — confers the highest risk of thrombotic events and represents the most clinically significant antibody profile. Patients with triple positivity have approximately 33% risk of a first thrombosis within 10 years and very high recurrence rates off anticoagulation.

Back to Table of Contents

Clinical Presentation

APS can affect virtually any organ system because its fundamental mechanism — thrombosis — can occlude vessels of any size anywhere in the body. The clinical picture depends on which vessels are affected.

Venous thromboembolism (VTE): Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the most common manifestations, occurring in roughly half of all APS thrombotic events. Unlike idiopathic VTE, APS-associated DVT frequently involves unusual sites such as axillary, portal, hepatic (Budd-Chiari syndrome), mesenteric, or renal veins.

Arterial events: Stroke and transient ischemic attack (TIA) are the most common arterial presentations, followed by myocardial infarction — particularly in young people (under 50) without traditional cardiovascular risk factors. APS should be in the differential for any young stroke.

Skin manifestations: Livedo reticularis — a mottled, net-like bluish discoloration of the skin — is present in up to 25% of APS patients and is a useful clinical clue, particularly when associated with thrombocytopenia or stroke (Sneddon's syndrome). Skin ulcers, digital ischemia, and superficial phlebitis also occur.

Hematologic features: Thrombocytopenia (platelet counts 50,000–100,000/µL) occurs in 20–30% of patients, caused by platelet consumption and antiplatelet antibodies. Coombs-positive hemolytic anemia may also occur. Paradoxically, both thrombocytopenia and APS do not protect against thrombosis — the net effect remains pro-thrombotic.

Cardiac involvement: Libman-Sacks endocarditis — sterile, verrucous vegetations typically on the mitral valve — is found by echocardiography in up to 11% of APS patients and can serve as a source of systemic emboli.

Obstetric manifestations: Recurrent early miscarriage, unexplained fetal death after 10 weeks, severe preeclampsia, HELLP syndrome (hemolysis, elevated liver enzymes, low platelets), intrauterine growth restriction, and placental abruption are the hallmark obstetric features.

Neurological symptoms beyond stroke: Cognitive difficulties ("brain fog"), memory impairment, migraine, chorea, epilepsy, and transverse myelitis have all been described in APS, suggesting that small-vessel disease or direct neuronal effects of aPL antibodies may contribute beyond macro-thrombosis.

Back to Table of Contents

Diagnosis

Diagnosing APS requires combining the clinical picture with a specific, standardized laboratory evaluation. No single test is sufficient; all three antibody types should be checked, and positive results must be confirmed on repeat testing at least 12 weeks later to exclude transient positivity from infection or other causes.

Lupus anticoagulant (LA) testing: Despite its confusing name, LA does not cause bleeding — it is a functional coagulation assay (not an antibody-specific test). The recommended method is the dilute Russell's viper venom time (dRVVT), performed in three steps: a prolonged screening test, a mixing study with normal plasma (a true inhibitor, unlike factor deficiency, will not fully correct), and a confirmatory phospholipid-rich neutralization step (which should shorten the clotting time). All three steps must be positive to report a true LA. This test is unreliable in patients already on anticoagulants — direct oral anticoagulants (DOACs) and heparin both interfere with the APTT-based and dRVVT-based assays.

Anticardiolipin (aCL) ELISA: The test must specify IgG and IgM isotypes separately — IgA is not part of the classification criteria. Medium-to-high titer positivity (≥40 GPL/MPL or >99th percentile) is required for criterion-level significance. Low-titer positivity is often nonspecific and may reflect transient infectious causes.

Anti-β2GPI ELISA: Anti-β2GPI IgG and IgM must be tested at internationally standardized units. IgG anti-β2GPI against domain I of the protein is the most specific marker for thrombotic risk.

Risk stratification by antibody profile: Triple positivity (LA + aCL + anti-β2GPI all positive) carries the highest thrombotic and obstetric risk. LA positivity alone, particularly at high titer, carries greater risk than isolated aCL or anti-β2GPI positivity. Isolated low-titer aCL positivity without LA or anti-β2GPI is the lowest-risk profile and warrants caution before attributing clinical events to APS.

Differential diagnosis: Other acquired or inherited thrombophilias (factor V Leiden, prothrombin G20210A mutation, protein C or S deficiency, antithrombin deficiency), heparin-induced thrombocytopenia (HIT), thrombotic thrombocytopenic purpura (TTP), and disseminated intravascular coagulation (DIC) must all be considered in the appropriate clinical context.

Back to Table of Contents

Treatment

Treatment of APS is divided into two main clinical scenarios: thrombotic APS (treating and preventing blood clots) and obstetric APS (preventing pregnancy complications). The cornerstone of both approaches is anticoagulation, but the specific agents, targets, and durations differ significantly.

Thrombotic APS — anticoagulation: Warfarin remains the gold standard for preventing recurrent thrombosis in confirmed thrombotic APS. For venous events, a target INR of 2–3 is established practice. For arterial events, recurrent thrombosis on warfarin, or triple-positive patients, a higher target INR of 3–4 is typically used, though evidence for the higher range is less robust. The TRAPS randomized controlled trial (2018) — the definitive study on this question — found that rivaroxaban (a DOAC) was non-inferior to warfarin for prevention of recurrent thrombosis in APS overall; however, in the subgroup of triple-positive patients, rivaroxaban showed significantly more arterial events and was inferior to warfarin. Based on this and subsequent data, direct oral anticoagulants are NOT recommended for high-risk thrombotic APS (triple-positive or arterial APS); warfarin remains preferred. DOACs may be considered for low-risk APS profiles (single antibody, venous only) in select patients who cannot maintain stable INR on warfarin.

Adjunct antiplatelet therapy: Low-dose aspirin (81 mg/day) is commonly added for patients with arterial events or additional cardiovascular risk factors, though definitive evidence for aspirin alone in secondary prevention of APS is limited.

Duration of anticoagulation: For the first unprovoked thrombosis in APS, most guidelines recommend indefinite anticoagulation given the very high recurrence rate (20–30% per year off therapy). For provoked events (e.g., post-surgery VTE) in a lower-risk aPL profile, a time-limited course may be considered, but this is controversial.

Obstetric APS — pregnancy management: The standard of care for women with APS and pregnancy complications is the combination of low-molecular-weight heparin (LMWH) and low-dose aspirin throughout pregnancy, starting as soon as pregnancy is confirmed. LMWH is preferred over unfractionated heparin for its predictable dosing and lower risk of heparin-induced osteoporosis. Warfarin crosses the placenta and is teratogenic in the first trimester. This combination increases live birth rates from approximately 50% without treatment to 70–80% in obstetric APS.

Hydroxychloroquine: In patients with secondary APS complicating SLE, hydroxychloroquine has independent anti-thrombotic properties (reduces platelet aggregation, inhibits aPL binding to β2GPI) and is recommended as background therapy for all SLE-APS patients. Some guidelines also consider it for primary APS, though evidence is weaker.

Primary prevention in asymptomatic aPL carriers: Individuals with positive aPL antibodies but no clinical events are a challenge. Low-dose aspirin is often recommended for high-risk profiles (triple positivity, lupus anticoagulant). General cardiovascular risk factor optimization (blood pressure control, smoking cessation, statin use) is important in all aPL carriers.

Back to Table of Contents

Catastrophic APS (CAPS)

Catastrophic APS — also called Asherson's syndrome — is a rare but life-threatening variant affecting fewer than 1% of all APS patients. It is defined by the rapid simultaneous or near-simultaneous occlusion of three or more organ systems within less than one week, caused by widespread small-vessel thrombosis producing a microangiopathic picture distinct from ordinary APS.

Clinical features: CAPS typically involves the kidneys (renal cortical necrosis, thrombotic microangiopathy), lungs (acute respiratory distress syndrome), brain (encephalopathy, stroke, cerebral infarctions), heart (myocardial infarction, cardiac failure), and adrenal glands (adrenal infarction). The combination of multi-organ involvement and systemic inflammatory response can mimic septic shock, TTP, or HIT, making early recognition difficult.

Triggers: An identifiable trigger is found in approximately half of CAPS cases. The most common are infections (particularly bacterial), surgical procedures, trauma, withdrawal of anticoagulation, and obstetric complications. In some patients, CAPS is the presenting manifestation of previously undiagnosed APS.

Pathophysiology of CAPS: Unlike the large-vessel thrombosis of classic APS, CAPS involves microvascular injury in which complement hyperactivation plays a central role alongside aPL-mediated endothelial damage, NET formation, and a cytokine storm-like state.

Treatment: CAPS requires intensive care management with a combination of full anticoagulation (intravenous heparin), high-dose corticosteroids, intravenous immunoglobulin (IVIG), and/or therapeutic plasma exchange (plasmapheresis). Rituximab (anti-CD20) has been used in refractory cases to deplete antibody-producing B cells. Eculizumab, a complement C5 inhibitor, has shown promise in CAPS by targeting the complement pathway central to its pathogenesis, though controlled trial data are limited. Despite aggressive treatment, mortality remains 30–50%, improving from over 50% in earlier eras with the addition of IVIG and plasmapheresis to anticoagulation.

CAPS Registry: Because of its rarity, CAPS is documented in an international registry (Euro-Phospholipid Project Group), which has been instrumental in defining its epidemiology and treatment outcomes. Clinicians encountering a CAPS case are encouraged to register it.

Back to Table of Contents

Prognosis and Long-Term Management

The prognosis of APS depends heavily on the antibody profile, the occurrence and type of first clinical event, the presence of underlying SLE or other comorbidities, and — critically — the consistency of anticoagulation management.

Recurrence risk off anticoagulation: Without ongoing anticoagulation, the annual recurrence rate for thrombotic APS is approximately 20–30% per year. This dramatically high rate of recurrence is the primary reason most guidelines recommend indefinite anticoagulation after a confirmed thrombotic event, unlike unprovoked VTE in the general population where limited-duration anticoagulation is sometimes acceptable.

Obstetric outcomes: With LMWH plus aspirin, live birth rates in obstetric APS approach 70–80%, compared to 50% or less without treatment. Women with prior thrombotic APS who become pregnant require continuation of therapeutic-dose anticoagulation throughout pregnancy and the postpartum period (the postpartum period is particularly high-risk for thrombosis).

Antibody persistence and fluctuation: aPL titers can fluctuate over time. Some patients with previously triple-positive profiles may lose one or more antibody types over years. However, conversion to antibody negativity should be confirmed on repeat testing over multiple years before considering anticoagulation withdrawal, and this decision should always involve a specialist.

Morbidity from long-term anticoagulation: Indefinite warfarin carries a 1–3% annual risk of major bleeding. Managing warfarin effectively requires frequent INR monitoring (typically every 2–4 weeks once stable), avoidance of interacting medications, and dietary consistency in vitamin K intake. Patients with a history of arterial APS or triple positivity face the difficult calculus of high recurrence risk against bleeding risk from higher-intensity anticoagulation.

Monitoring for secondary APS in SLE: APS patients with SLE should be monitored for lupus flares, which can precipitate thrombotic events. Hydroxychloroquine should be maintained and immunosuppressive therapy optimized. Cardiovascular risk factor management is essential in all APS patients, particularly those with arterial events.

Emerging therapies: Ongoing clinical trials are investigating complement inhibitors (eculizumab, belimumab combinations), B-cell depletion strategies (rituximab, obinutuzumab), and more targeted interventions against the β2GPI-antibody interaction. These approaches aim to address the underlying immune dysregulation rather than simply anticoagulating the downstream clotting cascade.

Back to Table of Contents

Research Papers

The following PubMed searches provide access to current peer-reviewed research on antiphospholipid syndrome.

  1. APS classification and revised Sapporo criteria — PubMed
  2. Lupus anticoagulant and thrombosis mechanisms — PubMed
  3. β2GPI as APS autoantigen and pathogenesis — PubMed
  4. TRAPS trial: warfarin vs rivaroxaban in APS — PubMed
  5. Obstetric APS: heparin and aspirin in pregnancy — PubMed
  6. Catastrophic APS (CAPS): treatment and outcomes — PubMed
  7. Complement activation in APS thrombosis — PubMed
  8. aPL antibodies and stroke in young adults — PubMed
  9. Triple positivity and thrombotic risk stratification in APS — PubMed
  10. Secondary APS in systemic lupus erythematosus — PubMed
  11. Hydroxychloroquine in APS thrombosis prevention — PubMed
  12. Eculizumab and rituximab as emerging APS therapies — PubMed

Back to Table of Contents

Connections

Back to Table of Contents